Banexi Ventures Partners  
Search :  
Home page | Contact us | Site map      

» About us
» Our expertise
» Team
» Portfolio
» News

» Contact us
» Home page

  About us

Banexi Ventures Partners is a French independent managing company. Banexi Ventures Partners invests through Venture Capital Funds, in early stage companies with high growth potential and high technology in 3 different sectors:

  • Internet
  • Electronic
  • Medical Technologies

Banexi Ventures Partners has been operating as BVP team Capital for 14 years :

  • 357 M€ invested since 1983
  • In 254 companies
  • 132 exits M&A (Kelkoo, Inventel,…) or IPO (Soitec, Exonhit, Aden Classified … )

Banexi Ventures Partners has paneuropean investors and some business angels who contribute with their expertise in their specific knowledge area.

Banexi Ventures Partners has a very close relationship with BNP Paribas Group due to its history (spin out).


Banexi Ventures Partners is commited to a sustainable investment policy by integrating the ESG (Environmental, Social and Governance) criteria (into their investment strategy).

Several actions have been implemented:
- A chart has been completed by Banexi Ventures Partners and signed by all the members of the team.
- Since October 2011 all new investments of BV5 FCPR complies with our ESG policy: from due diligence process to the lifetime of the investment.



Stopper le glaucome en une séance d'ultrasons
    » Read more

VEXIM lance officiellement une étude clinique internationale avec l’inclusion des premiers patients en préparation à sa demande d’autorisation règlementaire 510(k) pour commercialiser le SpineJack® aux États-Unis
    » Read more

EYE TECH CARE présente sa sonde « nouvelle génération »
    » Read more

VEXIM obtient l’autorisation de la FDA pour la commercialisation de son système d’injection MasterflowTM aux États-Unis
    » Read more

Symetis has TAVI big guns in its sights
    » Read more

Social Media Intelligence : Danone choisit Linkfluence sur 4 marchés clés de l’Europe de l’Ouest pour réaliser sa veille des médias sociaux et engager avec ses communautés
    » Read more

Symetis receives CE Mark approval for transfemoral transcatheter aortic heart valve system ACURATE neo™, and launches product with first commercial implantations
    » Read more

 Discover Portfolio Videos



Site web réalisé avec Clic Premium - version 4 / © innovation Partners, tous droits réservés.